Preview

Problems of Endocrinology

Advanced search

Adrenogenital syndrome: past, present, and future

https://doi.org/10.14341/probl201157166-70

Abstract

Adrenogenital syndrome is a group of pathological conditions with autosomal recessive inheritance underlain by the deficit of one of the enzymes involved in cortisol biosynthesis. The first clinical reports of patients with adrenogenital syndrome date back to the XIXth century. The literature of the early XXth century offers comprehensive clinical characteristics of the disease along with the first attempts at its classification. The progress in biochemistry and pharmacology in the mid-XX century provided knowledge for the explanation of the nature of adrenogenital syndrome and the development of methods of pathogenetically-grounded therapy of this pathology. The advent of the era of breakthroughs in molecular genetics was marked by the elucidation of underlying causes of congenital adrenal dysfunction. At present, neonatal screening makes it possible to diagnose adrenogenital syndrome in 100% of the patients and thereby ensure prevention of mortality from salt-losing crisis. Modern techniques are used not only for prenatal diagnostics but also for preimplantation prophylaxis of adrenogenital syndrome. At the same time, extensive investigations bring to light new forms of the disorder. Recent progress in genetics gives hope that even more efficacious methods of genotherapeutic modalities will be proposed for the management of chronic pathology in question.

About the Authors

M A Kareva



E M Orlova



References

1. Bongiovanni A.M., Root A.W. The adrenogenital syndrome. N Engl J Med 1963;268:1283-1289,1342-1351, 1391-1399.

2. Жуковский М.А., Бурая Т.И., Кузнецова Э.С. Врожденные дисфункции коры надпочечников у детей. М 1977.

3. Gallais A. Le syndrome génitosurrénal, étude anatomo-clinique. Paris 1912; 224.

4. Верещинский А.О. Надпочечно-половой синдром с точки зрения хирургической патологии и терапии. Вестн хир 1923;4:3:207-219.

5. Молчанов В.И., Давыдовский И.В. К клинике и патогенезу гирсутизма. Рус клин 1926;6:30:454-480.

6. Шерешевский Н.А. Клиническая эндокринология. М 1946.

7. Bartter F.C., Forbes A.P., Leaf A. Congenital adrenal hyperplasia associated with the adrenogenital syndrome: an attempt to correct its disordered hormonal pattern. J Clin Inv 1950;29:6:797.

8. Wilkins L. Adrenogenital syndrome due to enzymatic defects in cortisol synthesis. Am J Clin Nutr 1961;9:661-668.

9. Bartter F.C., Albright F., Forbes A.P. et al. The effects of adrenocorticotropic hormone and cortisone in the adrenogenital syndrome associated with congenital adrenal hyperplasia: an attempt to explain and correct its disordered hormonal pattern. J Clin Inv 1951;30:3:237-251.

10. Юдаев Н.А. Химические методы определения стероидных гормонов в биологических жидкостях. М 1961.

11. Bongiovanni A.M., Eberlein W.R. Plasma and urinary corticosteroids in the hypertensive form of congenital adrenal hyperplasia. J Biol Chem 1956;223:1:85-94.

12. Prader A., Siebenmann R.E. Nebenniereninsuffizienz bei kongenitaler Lipoidhyperplasie der Nebennieren. Helv Paediat Acta 1957;12:6:569-595.

13. Bongiovanni A.M. The adrenogenital syndrome with deficiency of 3-beta-hydroxysteroid dehydrogenase. J Clin Inv 1962;41:2086-2092.

14. Biglieri E.G., Herron M.A., Brust N. 17-Hydroxylation deficiency in man. J Clin Inv. 1966;45:12:1946-1954.

15. Васюкова Е.А., Моисеенко М.Д., Касаткина Э.П. Клиника и лечение врожденной дисфункции коры надпочечников. Гипофиз-кора надпочечников. Киев 1964;114-133.

16. Кузнецова Э.С. Отдаленные результаты лечения врожденной дисфункции коры надпочечников у детей. Всеросский съезд детских врачей, 3-й: Материалы. М 1969.

17. Раскин А.М. Врожденная вирилизирующая гиперплазия коры надпочечников. Пробл эндокринол 1962;6:88-97.

18. Старкова Н.Т. Основные этапы отечественных исследований в области изучения патогенеза, клиники и лечения заболеваний надпочечников. Пробл эндокринол 1965;5:29-38.

19. Бурая Т.И. Рост и развитие детей с врожденной дисфункцией коры надпочечников. Всеросский съезд детских врачей, 3-й: Материалы. М 1969.

20. Актуальные вопросы детской эндокринологии (труды I Всесоюзной конференции по детской эндокринологии). Под ред. Проф. М.А. Жуковского. Иваново 1972.

21. Pang S., Hotchkiss J., Drash A.L. et al. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1977;45:5:1003-1008.

22. Pang S., Spence D.A., New M.I. Newborn screening for congenital adrenal hyperplasia with special reference to screening in Alaska. Ann NY Acad Sci 1985;458:90-102.

23. Pang S.Y., Wallace M.A., Hofman L. et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988;81:6:866-874.

24. Prader A. Incidence of congenital adrenogenital syndrome. Helv. Paediatr Acta 1958;13:5:426-431.

25. Kagimoto M., Winter J.S., Kagimoto K. et al. Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: molecular basis of one example of combined 17 alpha-hydroxylase/17,20 lyase deficiency. Mol Endocrinol 1988;2:6:564-570.

26. Rhéaume E., Simard J., Morel Y. et al. Congenital adrenal hyperplasia due to point mutations in the type II 3-beta-hydroxysteroid dehydrogenase gene. Nat Genet 1992;1:4:239-245.

27. White P.C., Chaplin D.D., Weis J.H. et al. Two steroid 21-hydroxylase genes are located in the murine S region. Nature 1984;312:5993:465-467.

28. White P.C., Dupont J., New M.I. et al. A mutation in CYP11B1 (arg448-to-his) associated with steroid 11-beta-hydroxylase deficiency in Jews of Moroccan origin. J Clin Inv 1991;87:5:1664-1667.

29. Lin D., Sugawara T., Strauss J.F. 3rd et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995;267:5205:1828-1831.

30. Chrousos G.P., Evans M.I., Loriaux D.L. et al. Prenatal therapy in congenital adrenal hyperplasia. Attempted prevention of abnormal external genital masculinization by pharmacologic suppression of the fetal adrenal gland in utero. Ann NY Acad Sci 1985;458:156-164.

31. David M., Forest M.G. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr 1984;105:5:799-803.

32. Arlt W., Walker E.A., Draper N. et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004;363:9427:2128-2135.

33. Lin-Su K., Vogiatzi M.G., Marshall I. et al. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005;90:6:3318-3325.

34. Verma S., Vanryzin C., Sinaii N. et al. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxford) 2010;72:4:441-447.

35. Neufeld E.F., Sweeley C.C., Rogers S. et al. Gene therapy for human genetic disease? Science 1972;178:4061:648-649.

36. Van de Velde H., Sermon K., De Vos A. et al. Fluorescent PCR and automated fragment analysis in preimplantation genetic diagnosis for 21-hydroxylase deficiency in congenital adrenal hyperplasia. Mol Hum Reprod 1999;5:7:691-696.


Review

For citations:


Kareva M.A., Orlova E.M. Adrenogenital syndrome: past, present, and future. Problems of Endocrinology. 2011;57(1):66-70. https://doi.org/10.14341/probl201157166-70

Views: 1718


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)